- Recommendation ID
- HST1/2
- Question
- There is a need for further evidence on the long-term outcomes of treatment with eculizumab, and on the effect of treatment in children, adolescents and during pregnancy. The Committee supports enrolment of patients into the aHUS registry and the collection of high-quality information from these registries periodically to inform treatment decisions.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Eculizumab for treating atypical haemolytic uraemic syndrome
- Number
- HST1
- Date issued
- January 2015
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 09/02/2015 |